Delivery Order SPE2DB24D9313-SPE2DB25FFFLE

Award Date 6/3/25
Potential Completion Date 6/25/25
Potential Value $3.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a pharmaceutical product, with a ceiling value of $3,424.46 and a performance period ending on June 16, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $13,697.84 contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML pharmaceutical products, with a performance period ending on June 10, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of XOLAIR 300 mg/2 ml autoinjectors, with a ceiling value of $3,424.46 and a performance period ending on June 13, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,712.23 contract is for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a period of performance through June 13, 2025. DMS Pharmaceutical Group has a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,424.46 contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML and has a completion date of June 16, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a ceiling value of $5,136.69 and a completion date of May 8, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue firm...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $51,366.90 contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with an ultimate completion date of October 21, 2024. DMS Pharmaceutical Group holds a $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue firm...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of Xolair 300 mg/2 ml autoinjector, with a ceiling value of $10,273.38 and a period of performance through May 27, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a ceiling value of $5,127.14 and a completion date of June 9, 2025. DMS Pharmaceutical Group Inc. is an established pharmaceutical wholesaler that has secured a significant single-award Indefinite Delivery Contract (IDC) with the DLA under...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML pharmaceutical products, with a ceiling value of $8,561.15 and a completion date of June 27, 2025. DMS Pharmaceutical Group Inc. is a pharmaceutical wholesaler based in Park Ridge, Illinois, with a strong track record of supplying medical supplies and medications to...
  • SPE2DB24D9313
    Indefinite Delivery Contract
  • SPE2DB24D9313-SPE2DB25FFFLE
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a ceiling value of $3,424.46 and an ultimate completion date of June 25, 2025.

DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items supporting medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications.

Generated 9/2/25, 9:44 AM